EP300 single nucleotide polymorphism rs20551 correlates with prolonged overall survival in diffuse large B cell lymphoma patients treated with R-CHOP

[1] Alizadeh AA(2000)Distinct types of diffuse large B-cell lymphoma identified by gene expression profiling Nature 403 503-511

[2] Eisen MB(2010)Long-term outcome of patients in the LNH-98.5 trial, the first randomized study comparing rituximab-CHOP to standard CHOP chemotherapy in DLBCL patients: a study by the Grouped’Etudes des Lymphomes de l’Adulte Blood 116 2040-2045

[3] Davis RE(2008)Six versus eight cycles of bi-weekly CHOP-14 with or without rituximab in elderly patients with aggressive CD20 + B-cell lymphomas: a randomised controlled trial (RICOVER-60) Lancet Oncol 9 105-116

[4] Ma C(2005)Introduction of combined CHOP plus rituximab therapy dramatically improved outcome of diffuse large B-cell lymphoma in British Columbia J Clin Oncol 23 5027-5033

[5] Lossos IS(2006)Rituximab-CHOP versus CHOP alone or with maintenance rituximab in older patients with diffuse large B-cell lymphoma J Clin Oncol 24 3121-3127

[6] Rosenwald A(2011)Relapsed/refractory diffuse large B-cell lymphoma Hematol Am Soc Hematol Educ Progr 2011 498-505

[7] Boldrick JC(1999)The International Prognostic Index can be used as a guide to treatment decisions regarding patients with human immunodeficiency virus-related systemic non-Hodgkin lymphoma Cancer 86 2391-2397

[8] Sabet H(1996)The transcriptional coactivators p300 and CBP are histone acetyltransferases Cell 87 953-959

[9] Tran T(1996)The CBP co-activator is a histone acetyltransferase Nature 384 641-643

[10] Yu X(2011)The impact of acetylation and deacetylation on the p53 pathway Protein Cell. 2 456-462

[1] Alizadeh AA(2000)Distinct types of diffuse large B-cell lymphoma identified by gene expression profiling Nature 403 503-511

[2] Eisen MB(2010)Long-term outcome of patients in the LNH-98.5 trial, the first randomized study comparing rituximab-CHOP to standard CHOP chemotherapy in DLBCL patients: a study by the Grouped’Etudes des Lymphomes de l’Adulte Blood 116 2040-2045

[3] Davis RE(2008)Six versus eight cycles of bi-weekly CHOP-14 with or without rituximab in elderly patients with aggressive CD20 + B-cell lymphomas: a randomised controlled trial (RICOVER-60) Lancet Oncol 9 105-116

[4] Ma C(2005)Introduction of combined CHOP plus rituximab therapy dramatically improved outcome of diffuse large B-cell lymphoma in British Columbia J Clin Oncol 23 5027-5033

[5] Lossos IS(2006)Rituximab-CHOP versus CHOP alone or with maintenance rituximab in older patients with diffuse large B-cell lymphoma J Clin Oncol 24 3121-3127

[6] Rosenwald A(2011)Relapsed/refractory diffuse large B-cell lymphoma Hematol Am Soc Hematol Educ Progr 2011 498-505

[7] Boldrick JC(1999)The International Prognostic Index can be used as a guide to treatment decisions regarding patients with human immunodeficiency virus-related systemic non-Hodgkin lymphoma Cancer 86 2391-2397

[8] Sabet H(1996)The transcriptional coactivators p300 and CBP are histone acetyltransferases Cell 87 953-959

[9] Tran T(1996)The CBP co-activator is a histone acetyltransferase Nature 384 641-643

[10] Yu X(2011)The impact of acetylation and deacetylation on the p53 pathway Protein Cell. 2 456-462